Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 11/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | CFTR | P13569 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29354776 | 1.00 | FFAR4 (0.40) | FFAR4GLAPOLBGAATSHR | |
| SCHEMBL29616267 | 0.82 | KIF11 (0.41) | FFAR4GLAPOLBGAATSHR | |
| SCHEMBL1555044 | 0.78 | NOTUM (0.37) | GLAPOLBGAATSHRKIF11 | |
| SCHEMBL482274 | 0.77 | ALDH1A1 (0.33) | FFAR4GAATSHRFFAR1SMN1; SMN2 | |
| SCHEMBL29402330 | 0.76 | GAA (0.67) | FFAR4GLAPOLBGAATSHR | |
| SCHEMBL3534403 | 0.76 | GLA (0.54) | GLAPOLBGAATSHRAR | |
| SCHEMBL29403371 | 0.76 | KIF11 (0.50) | FFAR4GLAPOLBGAATSHR | |
| SCHEMBL670777 | 0.76 | GAA (0.67) | FFAR4GLAPOLBGAATSHR | |
| SCHEMBL349356 | 0.76 | KIF11 (0.50) | FFAR4GLAPOLBGAATSHR | |
| SCHEMBL6058773 | 0.76 | NOTUM (0.35) | GLAPOLBGAATSHRCFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11603350-B2 | Compound, composition, cured object, optically anisotropic body, and reflective film | FUJIFILM CORPORATION (JP) | 2023-03-14 | — | — | US | disclosed |
| US-11555026-B2 | AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2023-01-17 | — | — | US | disclosed |
| EP-3481819-B1 | COMPOUNDS AND THEIR USE FOR REDUCING URIC ACID LEVELS | ACQUIST LLC (US) | 2022-06-01 | — | — | EP | disclosed |
| US-20210236495-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2021-08-05 | — | — | US | disclosed |
| US-11020397-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210040326-A1 | AZACYANINE DYES AND USE THEREOF | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2021-02-11 | — | — | US | disclosed |
| US-10907099-B2 | Compound, composition, cured object, optically anisotropic body, and reflective film | FUJIFILM CORPORATION (JP) | 2021-02-02 | — | — | US | disclosed |
| US-10907099-B2 | Compound, composition, cured object, optically anisotropic body, and reflective film | FUJIFILM CORPORATION (JP) | 2021-02-02 | — | — | US | disclosed |
| US-20210017153-A1 | AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2021-01-21 | — | — | US | disclosed |
| US-20210017153-A1 | AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2021-01-21 | — | — | US | disclosed |
| WO-2015154725-A1 | QUINAZOLINE DERIVATIVE AND PREPARATION METHOD AND USE IN MEDICINE THEREOF | 四川海思科制药有限公司 | 2015-10-15 | — | — | WO | disclosed |
| EP-1861357-B1 | NOVEL COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORP (KR) | 2013-04-24 | — | — | EP | disclosed |
| WO-2012037108-A1 | AMINOQUINOLINE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037108-A1 | AMINOQUINOLINE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| US-7763657-B2 | Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same | AMOREPACIFIC CORPORATION (KR) | 2010-07-27 | — | — | US | disclosed |
| US-20090105258-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2009-04-23 | — | — | US | disclosed |
| WO-2007142426-A1 | NOVEL COMPOUNDS, ISOMER THEREOF OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2007-12-13 | — | — | WO | disclosed |
| EP-1862454-A1 | Novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and a pharmaceutical composition containing the same | Amorepacific Corporation (KR) | 2007-12-05 | — | — | EP | disclosed |
| EP-1861357-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Amorepacific Corporation (KR) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006101318-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11555026-B2 | AHR inhibitors and uses thereof | AHR, ARNT, AIPL1 | FFAR4 814/4885GLA 3423/4885POLB 3508/4885 |
| US-20210017153-A1 | AHR INHIBITORS AND USES THEREOF | AHR, ARNT, AIPL1 | FFAR4 814/4885GLA 3423/4885POLB 3508/4885 |
| US-20090105258-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | TRPV1, TRPA1, VIPR1 | FFAR4 202/4885GLA 4290/4885POLB 4833/4885 |
| US-10907099-B2 | Compound, composition, cured object, optically anisotropic body, and reflective film | CFL1, ADCY10, ADCY1 | FFAR4 66/4885GLA 3379/4885POLB 4265/4885 |
| US-20210040326-A1 | AZACYANINE DYES AND USE THEREOF | INMT, AZI2, MYADM | FFAR4 2664/4885GLA 1975/4885POLB 4325/4885 |
| US-20210236495-A1 | Compounds and Their Use for Reducing Uric Acid Levels | XDH, OAT, URB2 | FFAR4 1875/4885GLA 657/4885POLB 1802/4885 |
| US-11020397-B2 | Compounds and their use for reducing uric acid levels | XDH, OAT, UGT2B7 | FFAR4 702/4885GLA 1414/4885POLB 1797/4885 |
| US-11603350-B2 | Compound, composition, cured object, optically anisotropic body, and reflective film | FLNA, CFL1, MKI67 | FFAR4 611/4885GLA 3203/4885POLB 3314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.